Fluicell

Fluicell FCF Yield

The Free Cash Flow Yield of Fluicell (FLUI.ST) as of Nov 20, 2026 is -78.26 %. In the previous year, Free Cash Flow Yield was -151.60 % — a change of -48.38% (higher).

FCF Yield

-78.26 %

YoY

-48.38%

Last updated:

Free Cash Flow Yield of Fluicell is 2025 -78.26 % . Free Cash Flow Yield of Fluicell was 2024 -151.60 % . It decreases by -48.38% higher compared to the previous year.

The Fluicell FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-110.93 SEK
Jan 1, 2019
-141.49 SEK
Jan 1, 2020
-141.64 SEK
Jan 1, 2021
-153.60 SEK
Jan 1, 2022
-175.49 SEK
Jan 1, 2023
-215.44 SEK
Jan 1, 2024
-151.60 SEK
Jan 1, 2025
-78.26 SEK
The Fluicell FCF Yield history
YEARFCF YieldYoY
-78.26 %-48.38%
-151.60 %-29.63%
-215.44 %+22.76%
-175.49 %+14.25%
-153.60 %+8.45%
-141.64 %+0.11%
-141.49 %+27.55%
-110.93 %+68.28%
-65.92 %+49.30%
-44.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Free Cash Flow Yield of Fluicell is -78.26 % in 2025.

Free Cash Flow Yield of Fluicell changed from -151.60 % to -78.26 %, representing a -48.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Fluicell since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Fluicell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Fluicell

All Key Metrics — Fluicell